|
| 35022089 | Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed Glioblastoma. | Canadian Journal of Neurological Sciences | 2023 |
| 36180241 | In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of <i>IDH</i>-Mutant Diffuse Gliomas: The <i>IDASPE</i> Prospective Study. | Neurology | 2023 |
| 36400694 | Challenges in glioblastoma research: focus on the tumor microenvironment. | | 2023 |
| 36445254 | LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL. | Cancer Discov | 2023 |
| 36839777 | Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model. | | 2023 |
| 36898379 | Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. | Cancer Cell | 2023 |
| 37142871 | Late-onset vascular complications of radiotherapy for primary brain tumors: a case-control and cross-sectional analysis. | | 2023 |
| 36707509 | Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma. | Nat Commun | 2023 |
| 37262394 | Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma. | | 2023 |
| 36632791 | EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. | Neuro Oncol | 2023 |
| 36997420 | Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023). | Trends Cancer | 2023 |
| 36732634 | Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. | Nat Cancer | 2023 |
| 37531290 | Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA. | Neuro Oncol | 2023 |
| 37503540 | A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant. | | 2023 |
| 36915962 | Deciphering gliomagenesis from genome-wide association studies. | | 2023 |
| 35118384 | Mitochondrial DNA copy number as a prognostic marker is age-dependent in adult glioblastoma. | Neuro-Oncology Advances | 2022 |
| 36226710 | New insights into the Immune TME of adult-type diffuse gliomas. | Current Opinion in Neurology | 2022 |
| 35381117 | The influence of cystathionine on neurochemical quantification in brain tumor in vivo MR spectroscopy. | Magnetic Resonance in Medicine | 2022 |
| 35808822 | Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma. | Clin Transl Med | 2022 |
| 36456685 | Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response. | NPJ Precis Oncol | 2022 |
| 34272093 | [Meningiomas: A review of current knowledge]. | | 2022 |
| 35063776 | Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. | European Journal of Cancer | 2022 |
| 35275197 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. | Clin Cancer Res | 2022 |
| 34672349 | Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). | Neuro Oncol | 2022 |
| 34551969 | Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study. | Cancer Discov | 2022 |
| 34638742 | Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes. | International Journal of Molecular Sciences | 2021 |
| 34181595 | SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. | Journal of Clinical Investigation | 2021 |
| 33914057 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. | Neuro Oncol | 2021 |
| 33803924 | An AI-Powered Blood Test to Detect Cancer Using NanoDSF. | Cancers | 2021 |
| 33740099 | Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. | Acta Neuropathol | 2021 |
| 33787971 | Simultaneously acquired PET and ASL imaging biomarkers may be helpful in differentiating progression from pseudo-progression in treated gliomas. | European Radiology | 2021 |
| 34000245 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. | Lancet Oncol | 2021 |
| 33783067 | TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. | Oncologist | 2021 |
| 33778930 | Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. | J Neurooncol | 2021 |
| 33992635 | Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. | Gastroenterology | 2021 |
| 33986314 | Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. | Scientific Reports | 2021 |
| 34088874 | Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600-Mutant Adult Glial and Glioneuronal Tumors. | Neurology | 2021 |
| 33556177 | Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. | Neuro-Oncology | 2021 |
| 33173941 | IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. | Neuro-Oncology | 2021 |
| 33270257 | Current Management of Large Vestibular Schwannomas for NF2 Patients in a National Reference Center. | Laryngoscope | 2021 |
| 34550532 | PAK3 is a key signature gene of the glioma proneural subtype and affects its proliferation, differentiation and growth. | Cell Oncol (Dordr) | 2021 |
| 34815016 | Liquid biopsy in neuro-oncology: are we finally there? | Annals of Oncology | 2021 |
| 35005744 | Automated Acquisition Planning for Magnetic Resonance Spectroscopy in Brain Cancer. | Med Image Comput Comput Assist Interv | 2020 |
| 31969329 | Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. | Clinical Cancer Research | 2020 |
| 32322066 | Mechanisms and therapeutic implications of hypermutation in gliomas. | Nature | 2020 |
| 32025728 | High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts. | Neuro Oncol | 2020 |
| 32025725 | Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults. | Neuro Oncol | 2020 |
| 31965259 | Pseudo-continuous arterial spin labelling shows high diagnostic performance in the detection of postoperative residual lesion in hyper-vascularised adult brain tumours. | European Radiology | 2020 |
| 31743054 | Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. | J Clin Oncol | 2020 |
| 32413119 | Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. | Neuro Oncol | 2020 |